Technology | Treatment Planning | April 16, 2018

Varian Launches Velocity 4.0 Cancer Imaging Software

Latest release includes Rapidsphere module for Y90 selective internal radiation therapy dosimetry analysis

Varian Launches Velocity 4.0 Cancer Imaging Software

April 16, 2018 — Varian announced a new version of its Velocity cancer imaging software that includes Rapidsphere, a module for Y90 selective internal radiation therapy (SIRT) dosimetry analysis. Rapidsphere provides the ability for cancer care teams to better understand tumor response and normal-tissue toxicity for individual patients receiving SIRT. This new software module extends Varian's Velocity software to interventional radiologists for use in targeted cancer therapy delivery to patients with liver malignancies.

Velocity 4.0 and the Rapidsphere module have received U.S. Food and Drug Administration (FDA) 510(k) clearance.

Rapidsphere runs on the Velocity software platform, which aggregates unstructured treatment and imaging data from diverse systems to show a comprehensive view of a patient's diagnostic imaging and treatment history. Rapidsphere is an integrated image-guided dosimetry system for calculating the absorbed dose using post-treatment emission tomography imaging from Y90 SIRT.

Velocity 4.0 incorporates several new features or improved functionalities. Additional new features in the software include:

  • Velocity M3i (Multi-Modality Motion Imaging) — Simultaneous display and contouring of up to 10 imaging studies; (CT/MR/PET/SPECT/Ultrasound/4DCT/CBCT) with deformable image registration;
  • Velocity Aria Sync — Automatic synchronization of approved objects from Aria and Eclipse and one-click save of Velocity data with Aria and Eclipse; and
  • Velocity Tumor & Dose Tracking – Image-based tumor and radiotherapy dose tracking across multiple treatment courses and therapy modalities to verify both volumetric tumor change and the cumulative dose history for cancer patients

For more information: www.varian.com

 

Related Content

Elekta Harmony linear accelerator cleared by U.S. Food and Drug Administration
News | Linear Accelerators | June 18, 2021
June 18, 2021 — Elekta announced that its Elekta Harmony...
The impact of deploying artificial intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.

Getty Images

News | Artificial Intelligence | June 15, 2021
June 15, 2021 — The impact of deploying ...
Accuray Incorporated announced the company has received CE Mark certification for its ClearRT helical fan-beam kVCT imaging capability.
News | Radiation Therapy | June 11, 2021
June 11, 2021 — Accuray Incorporated announced the company has received CE Mark certification for its...
Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

Prof. Jayant Vaidya, lead author of the study, University College London surgery and interventional science, performs a TARGI-IORT procedure. A small ball-shaped device placed inside the breast, directly where the cancer had been. The single-dose treatment lasts for around 20-30 minutes and replaces the need for extra hospital visits in eight out of ten cases.

News | Radiation Oncology | June 02, 2021
June 2, 2021 — A breast cancer therapy that requires just one shot of radiotherapy is as effective as traditional rad
The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

The experimental drug avasopasem manganese protects healthy tissue while enhancing radiation's capacity to kill cancerous tumor cells by converting superoxide to hydrogen peroxide. Image courtesy of Michael Story, Ph.D.

News | Radiation Therapy | May 21, 2021
May 21, 2021 — An experimental drug that has shown promise in protecting healthy tissue from collateral damage caused
The drug, known as Avasopasem manganese, is made by Galera Therapeutics. It acts like a natural enzyme called superoxide dismutase and converts superoxide into hydrogen peroxide. Based on its ability to "mop up" damaging superoxide molecules, which are produced by radiation treatment, the drug is currently in clinical trials to test its ability to protect mucosal tissue from the side-effect of radiotherapy.

Getty Images

News | Radiation Therapy | May 19, 2021
May 19, 2021 — A small drug molecule that appears to protect normal tissue from the damaging effects of...